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Contrasting effects of linezolid 
on healthy and dysfunctional 
human neutrophils: reducing 
C5a‑induced injury
Stephen J. Evans1, Aled E. L. Roberts1, Andrew Conway Morris2, A. John Simpson3, 
Llinos G. Harris1, Dietrich Mack1,4, Rowena E. Jenkins1 & Thomas S. Wilkinson1*
Methicillin‑resistant Staphylococcus aureus (MRSA) is an important cause of ventilator‑associated 
pneumonia (VAP). Patients with VAP have poorly functioning neutrophils, related to increased 
levels of the complement fragment C5a. The antibiotic linezolid has been useful in controlling 
MRSA‑related VAP infections; however clinical benefit does not always correlate with antimicrobial 
effect, suggesting the possibility of immunomodulatory properties. Here the effects of linezolid on 
healthy and dysfunctional neutrophils (modelled by C5a‑induced injury) was investigated. Functional 
assays (killing, phagocytosis, transmigration, and respiratory burst) were used to assess the effects 
of pre‑, co‑ and post‑incubating linezolid (0.4–40 mg/L) with healthy neutrophils relative to those 
with C5a‑induced injury. C5a decreased neutrophil killing, and phagocytosis of MRSA. Furthermore, 
C5a significantly decreased neutrophil transmigration to IL‑8, but did not affect respiratory burst. 
Co‑incubation of linezolid significantly improved killing of MRSA by dysfunctional neutrophils, 
which was supported by concomitant increases in phagocytosis. Conversely linezolid impaired killing 
responses in healthy neutrophils. Pre‑ or post‑incubation of linezolid prior or following C5a induced 
injury had no effect on neutrophil function. This study suggests that linezolid has immunomodulatory 
properties that protect human neutrophils from injury and provides insight into its mode of action 
beyond a basic antibiotic.
Ventilator-associated pneumonia (VAP) is an important infection acquired in the intensive care unit (ICU) 
and can occur in up to 20% of patients mechanically ventilated for periods greater than 48  h1. The 2016 annual 
European report on healthcare-associated infections showed that of 12,735 patients staying more than 2 days 
in ICU, 6% developed pneumonia (where 97% of these were intubated), with Staphylococcus aureus the causa-
tive organism in 17.8% of cases (30% being methicillin-resistant S. aureus (MRSA))2. Treatments for MRSA 
pneumonia have relied on vancomycin and teicoplanin until the introduction of linezolid in 2000, which has 
been particularly successful at treating MRSA  pneumonia3–5. While it is clear that linezolid has a  clinical3–5 and 
economic  benefit6,7 in treating MRSA pneumonia, the apparent treatment effect is not due to its antimicrobial 
activity  alone3,8, suggesting potential host-specific effects, such as immunomodulation.
The underlying illness in critically ill patients, including those with VAP, is often associated with major 
deficiencies in the innate immune  system9 specifically, neutrophil dysfunction, an inability to phagocytose or 
produce a respiratory  burst10,11. Our previous studies found that VAP patients’ neutrophils had 36% lower phago-
cytic capacity than healthy volunteers, and was significantly and negatively correlated with serum C3a des-Arg 
(C3a breakdown product) and positively correlated with neutrophil cell surface expression of the C5a receptor 
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(CD88). In vitro modelling in healthy volunteer neutrophils found that C5a treatment could mimic impaired 
phagocytosis and down-regulate  CD8812–14.
The effect of linezolid on dysfunctional human neutrophils has not been studied to date. However, numerous 
studies have addressed the effects of linezolid on neutrophils from healthy volunteers. For instance, linezolid 
at concentrations of 10–160 mg/L, had no negative effects on chemotaxis or respiratory burst in either a pure 
drug or intravenous injection  formulation15. Similarly, pre-incubation of healthy neutrophils with linezolid 
(2–20 mg/L) had no effect on phagocytosis of methicillin-resistant or -susceptible S. aureus, or Enterococcus 
faecalis (vancomycin-resistant or -susceptible)16. Other studies have shown small decreases in phagocytosis in 
response to certain strains of Escherichia coli17. Interestingly, Pascual and co-workers have shown that linezolid 
penetrates the neutrophil rapidly as intracellular concentrations greater than those of the external environment 
are reached within 20  min18. This ability to cross biological membranes is reflected in its high concentrations in 
lung epithelial lining fluid (ELF). These studies suggest that linezolid in concentrations far in excess of its MIC 
(4 mg/L)19 are not cytotoxic to healthy neutrophils using a variety of functional assays.
Using our established model of C5a-induced neutrophil  dysfunction12,13, we investigated the effect of linezolid 
on both healthy and clinically relevant C5a-impaired neutrophils in a variety of relevant functional assays.
Results
Killing response of neutrophils to VAP39 resulted in ~ 50% decrease in colony counts over the first 2 h of infec-
tion (Fig. 1A). MRSA incubated without neutrophils doubled in number over the same period showing strain 
viability in our assay media. Incubation of neutrophils with increasing doses of C5a (1–100 ng/ml) resulted in a 
Figure 1.  Effects of C5a on neutrophil function: killing and phagocytosis. Purified neutrophils were treated 
with or without C5a (1–100 ng/ml) for 16 h prior to functional assay. (A) Killing expressed as viable counts 
of MRSA (cfu/ml). (B) Phagocytosis expressed as the percentage of neutrophils containing MRSA. Data are 
expressed as the mean ± SEM of 4 separate donors. *Represents a significant difference between viable counts of 
MRSA at t = 0 versus t = 2 with neutrophils present. **Represents a significant difference between viable counts 
of MRSA at t = 2 with neutrophils present versus t = 2 with neutrophils present treated with C5a at 100 ng/ml. 
***Represents a significant difference in phagocytosis between neutrophils treated and not treated with C5a.
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significant increase in the survival of MRSA at the highest dose of C5a (100 ng/ml) demonstrating dysfunctional 
killing responses. Consistent with this result a significant decrease (p < 0.05) was detected in neutrophil phago-
cytosis of VAP39 (Fig. 1B and Supplementary Image 2) over 2 h. Thus C5a (100 ng/ml) decreased neutrophil 
killing which is associated with attenuated phagocytosis (Fig. 1A,B).
The effect of C5a on the ability of neutrophils to transmigrate across membrane filters in response to IL-8 
was investigated (Fig. 2A). IL-8 induced a significant increase (p < 0.05) in neutrophil transmigration (Fig. 2 and 
Supplementary image 3). Addition of C5a caused a dose-dependent decrease in IL-8-induced transmigration 
which reached significance (P < 0.05) at the highest dose of C5a (100 ng/ml). In contrast, while neutrophil res-
piratory burst (Fig. 2B) was significantly induced (p < 0.05) using PMA it was independent of C5a over the dose 
range studied. Collectively these results (Figs. 1 and 2) demonstrate that functional responses (without C5a) and 
dysfunctional responses (with C5a at 100 ng/ml) can be produced in killing, phagocytosis and transmigration. 
Neutrophils are viable as confirmed by full respiratory burst in healthy and dysfunctional neutrophils (Fig. 2B). 
Neutrophil metabolic activity measurements using alamar blue confirmed that cellular reducing power decreased 
up to 10% and 45% in functional and dysfunctional neutrophils respectively (data not shown) and is consistent 
with a recent study confirming the effects of C5a on cellular  respiration20. Using these two conditions (with and 
without C5a at 100 ng/ml) the effect of linezolid on functional and dysfunctional neutrophils was investigated.
Functional (grey bars) and dysfunctional neutrophils (black bars) were generated and co-incubated with 
linezolid during the C5a incubation period (Fig. 3). Functional neutrophils killed MRSA over 2 h (white bar 
vs. first grey bar in Fig. 3A), whereas linezolid had no effect on killing by functional neutrophils (Fig. 3A, grey 
bars). This result also confirms there was no anti-bacterial effect from linezolid carried over inside neutrophils. 
In contrast, linezolid significantly improved (at 40 mg/L) killing of VAP39 in dysfunctional neutrophils (Fig. 3A, 
black bars). Indeed, the killing response was no different to that produced initially in functional neutrophils (first 
Figure 2.  Effects of C5a on neutrophil function: transmigration and respiratory burst. (A) Transmigration 
is expressed as the number of cells counted per high power field. (B) Respiratory burst is expressed as the 
amount of superoxide release per million cells. Data are expressed as the mean ± SEM of 4 separate donors. 
Differences between groups were calculated using ANOVA with a Tukey’s post-hoc test where p < 0.05 
considered significant. *Represents a significant difference between neutrophil transmigration with and without 
IL-8. **Represents a significant difference between IL-8 stimulated neutrophils treated with and without C5a. 
#Represents a significant difference in respiratory burst between neutrophils stimulated with PMA and those 
without PMA.
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grey bar vs. final black bar) showing that linezolid could prevent C5a-induced injury in neutrophils when co-
incubated with C5a. Further investigation confirmed that linezolid, co-incubated with C5a could also attenuate 
the defect induced in phagocytosis of MRSA (Fig. 3B). Thus, linezolid appears to improve killing by dysfunctional 
neutrophils by improving phagocytosis. This mechanism was only observed during co-incubation and not when 
linezolid was incubated prior to or after the C5a-injury period (Supplementary Figs. 2 and 3). Further assessment 
of neutrophil metabolic activity by alamar blue confirmed that linezolid decreased (10–20%) the reducing power 
of neutrophils after 1 h (pre and post-incubation protocols) and by 10–30% over 16 h (co-incubation) (Supple-
mentary Fig. 4) when given alone. In the absence and presence of C5a, the reducing power of the cell decreased 10 
and 50% respectively and is consistent with a recent study confirming the effects of C5a on cellular  respiration20. 
The effect of linezolid on IL-8-induced transmigration was then assessed by co-incubating functional and 
dysfunctional neutrophils with linezolid during C5a incubation period (Fig. 4). In functional neutrophils, lin-
ezolid caused a significant dose dependent decrease in transmigration (Fig. 4, grey bars), while having no effect 
on the transmigration of dysfunctional neutrophils (Fig. 4, black bars). Furthermore, pre-incubation or post-
incubation with linezolid prior or after the C5a injury period had no significant effects on transmigration, 
(Supplementary Fig. 5A and B).
Figure 3.  Effects of linezolid on functional and dysfunctional neutrophil killing and phagocytosis. (A) Killing 
expressed as viable counts of MRSA (cfu/ml). (B) Phagocytosis expressed as the percentage of neutrophils 
containing MRSA. Data are expressed as the mean ± SEM of 4 separate experiments. White bar represents viable 
MRSA at t = 0. Hatched bar represents viable MRSA at t = 2 without neutrophils. Grey and black bars represent 
neutrophils at t = 2 without and with C5a respectively. *Represents a significant difference between viable counts 
of MRSA at t = 0 versus t = 2 with neutrophils present. **Represents a significant difference between viable 
counts of MRSA treated with functional and dysfunctional neutrophils at t = 2. ***Represents a significant 
difference between viable counts of MRSA exposed to dysfunctional neutrophils treated with or without 
linezolid. # Represents a significant difference in phagocytosis of MRSA by functional and dysfunctional 
neutrophils. ## Represents a significant difference in the phagocytosis of MRSA by dysfunctional neutrophils 
with or without linezolid.
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Finally, the effects of linezolid on respiratory burst (Fig. 5) were assessed by adding PMA to functional and 
dysfunctional neutrophils respectively. A significant respiratory burst response to PMA could be generated in 
functional (Fig. 5, grey bars) and in dysfunctional neutrophils (Fig. 5, black bars) but linezolid had no effect 
on this PMA induced response (Fig. 5). Samples that were not stimulated by PMA but included combinations 
with and without C5a or linezolid were not significantly increased compared to negative control in Fig. 5. The 
fact that a full respiratory burst could be induced in dysfunctional neutrophils, albeit independent of linezolid, 
encouraged us to investigate whether pre-incubation and post-incubation of linezolid prior to and after C5a 
induced injury may be affected (Supplementary Fig. 6). The results showed increased trends in respiratory 
burst at lower doses of linezolid (0.4 and 4 μg/ml) but not at the highest dose (40 mg/L) for both functional and 
dysfunctional neutrophils.
Discussion
The current study extends our previous model of C5a-induced dysfunction in response to P. aeruginosa12,13 and 
S. epidermidis biofilm accumulation in whole  blood21 to investigate the potential of the oxazolidinone, linezolid, 
to modulate important innate immune responses in healthy and dysfunctional neutrophils. Concentrations of 
Figure 4.  Effects of linezolid on functional and dysfunctional neutrophil IL-8 induced transmigration. 
Grey and black bars represent functional and dysfunctional neutrophils, respectively. Data expressed as the 
mean ± SEM of 4 separate experiments. *Represents a significant difference between the transmigration of 
functional and dysfunctional neutrophils. **Represents a significant difference between the transmigration of 
neutrophils treated with linezolid (40 mg/L) and those without.
Figure 5.  Effects of linezolid on functional and dysfunctional neutrophil respiratory burst. Grey and black bars 
represent functional and dysfunctional neutrophils, respectively following treatment with PMA and linezolid. 
Data expressed as the mean ± SEM of 4 separate experiments. *Represents a significant difference between PMA 
treated and untreated functional neutrophils (grey bars). # Represents a significant difference between PMA 
treated and untreated dysfunctional neutrophils (black bars).
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C5a measured in BAL during lung infection range from 20 to 180 ng/ml22,23. The current study used 1–100 ng/
ml C5a to induce dysfunction in MRSA killing, phagocytosis and transmigration, but retain a functional res-
piratory burst. This is in keeping with our previous work on S. epidermidis biofilm where C5a concentrations 
of up to 80 ng/ml were generated ex vivo21. Taken together our current and previous neutrophil killing and 
phagocytosis results using P. aeruginosa, S. aureus and S. epidermidis suggest that neutrophil sensitivities to 
clinically relevant C5a concentrations may well be dependent on bacterial species when investigating killing and 
phagocytosis responses.
There is now very clear scientific evidence, defining the metabolic and signalling pathways underlying func-
tional  neutrophils24 and those subjected to C5a-induced  dysfunction12,13,20,25. Thus, ligation of C5aR1 (CD88) 
by C5a, activates its inherent G-protein activity resulting in phosphoinositide 3-kinase delta (PI3Kδ) activation 
inhibiting activation of the small GTPase RhoA, actin polymerisation and  phagocytosis13. At the time of writing 
Wood and co-workers confirmed that C5a induced decreases in the phagocytosis of S. aureus are associated with 
impaired phagosomal maturation by phosphoproteomic remodelling through selective impairment of phagoso-
mal protein phosphorylation, including endosomal marker ZFYVE16 and V-ATPase protein channel component 
 ATPV1G125. In addition, Denk and co-workers proposed that C5aR1 ligation also leads to selective activation 
of the  Na+/H+ exchanger causing increased intracellular alkalinisation (pHi), increased glycolytic flux, glucose 
uptake and lactate and proton  excretion20. In the current study, alamar blue assessment of the reducing power 
of the cells also confirmed 50% decreased in response to C5a. This is consistent with broad metabolic defects 
observed in immune cells (immunoparalysis) and characterised by a switch from oxidative phosphorylation 
to aerobic  glycolysis26. Indeed, a deficit in energy status (nutrition delivered—energy expenditure) has been 
reported as a risk factor for the development of S. aureus  VAP27. These effects also appear reversible, as GM-CSF 
can reverse the effects of C5a-induced injury by reactivating RhoA at the cellular  level13 and can improve neu-
trophil phagocytosis in critically ill  patients28. Furthermore, others have shown that IFN-γ can partially restore 
function in immunoparalysed  leukocytes26.
The present study showed that C5a has little effect on oxygen radical killing mechanisms, unlike a study by 
Huber–Lang which demonstrated C5a-induced impairment of ROS production and failure of NADPH oxidase 
 assembly29. Indeed our previous work could not demonstrate C5a impairment of ROS either, but did find that 
it could be negatively correlated with C3a des-Arg (C5a degradation product) levels in the serum of critically 
ill  patients12,13. This may be attributed to functional differences in rat and human neutrophils. Clearly, the C5a 
effect we observe is independent on the method of superoxide radical production. In our previous study, neutro-
phils were primed with 100 nM platelet-activating factor (PAF) and stimulated with 100 nM formyl methionyl 
leucyl phenylalanine (fMLP), whilst in the current study a single PMA induction was used. Alternatively, kill-
ing mechanisms in the current study may be protease-mediated, as we have shown previously for neutrophil 
dysfunction in the  lung30.
Choosing appropriate doses of linezolid was important during experimental design of this study. There 
were three major considerations behind our rationale; firstly, to approximate cellular exposure such as in the 
epithelial lining fluid (ELF), intracellularly and serum concentrations in humans; secondly, to take into account 
antibiotic concentrations in health and disease; and thirdly to consider defined MIC breakpoints for antibiotic 
and pathogen. Numerous pharmacokinetic studies and reviews have addressed these  issues31–34. For example 
pharmacokinetic studies in humans confirmed that 600 mg of oral linezolid resulted in mean concentrations of 
7.6, 24.3 and 1.4 mg/L 12 h later in plasma, ELF and alveolar cells  respectively31. The EUCAST breakpoint for 
linezolid on MRSA is 4 mg/L19. Thus, our decision to use linezolid at 0.4, 4 and 40 mg/L was well justified as these 
concentrations are very likely to contact neutrophils in both injured and uninjured lung.
Three linezolid incubation conditions were used to investigate effects on functional and dysfunctional neu-
trophils and included, pre-, co-, and post C5a incubation period strategies. The rationale being that protection, 
inhibition and restoration of neutrophil function could be measured respectively. The current study showed 
very clearly that linezolid’s effects were produced solely using the co-infection strategy. Thus, speculation on 
linezolid’s targets must draw evidence from C5a signalling processes and emphasise the importance of the C5aR1 
(CD88) cell surface receptor, the PI3Kδ-RhoA pathway, phagosome maturation and modulators of glycolytic 
flux such as glucose transporters and  pHi12,13,20,25. Critically, Wood et al. alluded to the timing of exposure to 
C5a as important in downstream  effects25. They find that C5a only impairs phagocytosis if the cells are exposed 
to it before they encounter S. aureus—not at the same time or after initial exposure. This effect is independent 
of CD88. In the current study it seems reasonable to assume that co-infection with linezolid must influence 
this critical C5a signalling period and its effect is independent of cell surface CD88, but dependent on effects 
produced intracellularly on pHi or maturation of the  phagosome20,25.
Further insight into the cellular effects of linezolid may be gained when viewed anatomically. There is good 
evidence for linezolid penetration into the intracellular compartment of  cells33, thus binding and biological 
activity at the level of organelles is likely. Interestingly, sufficient patient data now exist on the inhibitory effect 
of linezolid on protein synthesis in the mitochondria leading to anaerobic glycolysis and cellular  acidosis35–38. 
Specifically with respect to the neutrophil, the mitochondrion has evolved a specific function in apoptosis (not 
ATP production) and contains numerous apoptotic  proteins39. There is an intriguing possibility for linezolid to 
modify neutrophil function in a state-dependent (function/dysfunction) manner as shown in this work. However 
a recent study by Akinnusi and co-workers could not show any effect of linezolid on neutrophil apoptosis in a 
MRSA pneumonia mouse  model40.
In healthy neutrophils, linezolid produced a significant dose-dependent decrease in transmigration. This 
is partly supported by other studies which showed either no effect on neutrophil  functions15,16 or mild toxic 
responses in  phagocytosis17 over similar dose ranges (0–160 mg/L) to our study (0.4–40 mg/L). The trends 
towards enhanced respiratory burst observed in this study may be due to the much shorter incubation times 
(1 h) which may generate a priming effect as with a PAF/fMLP combination shown  previously12. One strength 
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of the current study is extension of this work to dysfunctional cells which are more likely to be present in the 
critically ill patient who receives linezolid. Two major findings are particularly pertinent; (1) linezolid inhibited 
C5a-induced dysfunction in neutrophil killing; (2) linezolid inhibited C5a induced dysfunction in neutrophil 
phagocytosis. Firstly, these results suggest that the effects of C5a are reversible. Secondly, they support previous 
observations in clinical studies, where clinical benefit could not be explained by antimicrobial activity  alone3,8. We 
speculate that linezolid’s inhibition of C5a-induced dysfunction (under co-incubation conditions only) could be 
responsible for a large proportion of the underlying mechanism on clinical benefit. Thus, less neutrophils would 
become dysfunctional in the presence of C5a. Indeed, if this were the case the inhibitory effect that linezolid 
has on functional neutrophil transmigration may now come into play and also reduce the excessive inflamma-
tion seen in the lung during pneumonia. This is compelling as there are already numerous reports that suggest 
linezolid modulates cytokine  cascades41–46. Furthermore, such effects on healthy and dysfunctional neutrophils 
raise the interesting novel possibility that linezolid’s action could be dependent on the state of the cell. This is 
analogous to antibiotics having activity on dividing cells but not on dormant  bacteria47.
There is a growing literature that suggests that linezolid has an advantage over glycopeptides such as van-
comycin and teicoplanin in the treatment of proven MRSA  pneumonia3–5,48,49. At least four potential reasons 
underlie this effect. Firstly, concentrations in ELF can consistently exceed the MIC breakpoint (4 mg/L) needed 
for adequate antimicrobial  activity31,34,48,50 with concentrations reported to stay above MIC levels 100% of the 
 time31. Secondly, vancomycin is associated with renal toxicity and  neutropenia51. Thirdly, protein synthesis 
inhibition by linezolid produces a ‘non-bacteriolytic’ action and reduces virulence factor  expression52–54. Finally, 
linezolid may affect host cell functions and cytokine  networks41–46. Indeed, a recent experimental infection model 
of MRSA pneumonia and clinical studies in community-acquired MRSA pneumonia suggest protective immu-
nomodulatory effects of  linezolid55,56. These studies lend support to the hypothesis that linezolid has ‘additional’ 
antimicrobial efficacy through mechanisms involving immunomodulation.
We accept that this study is not without limitations. Firstly, we did not investigate the effects of glycopeptides 
(such as vancomycin) on neutrophils. We did investigate vancomycin as a potential control early in this study 
but found that dosing was inconsistent especially when combined with C5a in the dysfunctional model and 
thus did not pursue this further. However, the effects of vancomycin on neutrophils have been well  studied57–60, 
and it is interesting to note that dosing remains a difficulty following 60 years of  use61. Secondly, this study used 
one strain of MRSA (VAP 39) from our previous  studies12, but selected appropriately with justification from a 
choice of 6 strains (Table 1 and supplementary Fig. 1). This allowed the current study to focus on intricate cell 
biology. Future work will investigate these effects across the wider S. aureus species. Thirdly, we also undertook 
preliminary experiments with cellular inhibitors (e.g. cytochalasin D and MAP kinase inhibitors) as we have done 
 previously12,13,21,62, however the use of three reagents (C5a, linezolid and inhibitor) resulted in overwhelming cell 
toxicity (95–100% cell death) and were discontinued. Fourth, studies using C5a to investigate its effects in assays 
of neutrophil function/dysfunction should take care in design as chemotactic agents can have contrasting effects 
and lead to neutrophil priming/de-priming  responses63–65. Finally, studies such as this could be applied to the 
next generation of novel oxazolidinone and anti-staphylococcal agents, such as tedizolid, which has potential 
for treating MRSA  infections66.
To conclude, this study confirms that linezolid has immunomodulatory properties that protect human neu-
trophils from injury and provides insight into its mode of action beyond a basic antibiotic. These results will go 
some way in explaining why the therapeutic/treatment effect of linezolid is greater than its antimicrobial activity.
Materials and methods
All methods were carried out in accordance with relevant guidelines and regulations.
Bacterial strains and determination of MIC. Six clinical MRSA isolates obtained from bronchoalveolar 
alveolar fluid (BAL) in our previous studies were used (Table 1)12,13, and methicillin-sensitive S. aureus Cowan 
1 was used as a control strain. Linezolid and vancomycin MICs were determined by using the limiting dilution 
Table 1.  VAP and non VAP MRSA strains. Six MRSA strains were used and clinically defined as VAP or non 
VAP from a previous  study12. Column 1 shows isolates detected in the original study with MRSA isolated 
and sub-cultured to produce the work in this manuscript. The strain used throughout this study, VAP39, is 
highlighted in bold.
Organism(s) Strain Islolated from CFU/ml VAP (+ / −)
Antibiotic MIC (μg/ml)
Linezolid Vancomycin
H. influenzae
S. aureus (MRSA) VAP 025 BAL
104
103  + 4 (S) 1 (S)
S. aureus (MRSA) VAP 026 BAL 102  − 4 (S) 0.5 (S)
S. aureus (MRSA) VAP 032 ETA 106  − 4 (S) 1 (S)
H. influenzae
S. aureus (MRSA) VAP 034 BAL + ETA
104
104  + 4 (S) 1 (S)
S. aureus (MRSA) VAP 039 BAL 104  + 4 (S) 1 (S)
Aspergillus spp.
S.aureus (MRSA) VAP 040 BAL
102
103  − 4 (S) 1 (S)
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method. Briefly, MRSA isolates were grown in tryptic soy broth ((TSB); Becton Dickinson, Cockeysville, USA)) 
overnight at 37 °C, then washed and resuspended to an  OD600 = 0.1 (~ 1 × 107 cfu/ml). MRSA isolates (5 × 105 cfu) 
were then added to a 96-well plate containing a dilution series of linezolid (0.25–256 mg/L final) in TSB and 
incubated overnight at 37 °C. Plates were examined the following day and the lowest concentration of linezolid 
inhibiting visible growth determined. Antimicrobial sensitivity was compared to current EUCAST  guidelines19.
Selection of MRSA strain VAP 39. To select an appropriate MRSA strain for these studies all six MRSA 
isolates from our previous studies were tested for their sensitivity to linezolid and vancomycin (Table 1). Strains 
were isolated from the bronchoalveolar alveolar fluid (BAL) of patients, with 3 coming from patients with bacte-
rial growth > 104 colony-forming units/ml (CFU/ml) of lavage fluid, and 3 with growth below this conventional 
cut-off for the diagnosis of VAP. All strains had consistent MIC values for linezolid (4 μg/ml) and for vanco-
mycin (1 μg/ml) except VAP26 (0.5 μg/ml). Thus, all MRSA strains were sensitive to linezolid and vancomycin 
by EUCAST  guidelines19. Further consideration (Table 1) of the specificity of the source (BAL only) confirmed 
VAP39 as the test isolate for further studies. In addition, VAP39 was appropriate for downstream leukocyte 
assays, as comparisons between VAP39, VAP26 and laboratory reference, methicillin-sensitive S. aureus Cowan 
1 strain showed no differences in killing and phagocytosis assays (Supplementary Fig. 1A–D). Therefore, VAP39 
was selected for use in the remaining experiments.
Bacterial culture for functional assays. One colony of MRSA VAP39 was inoculated into TSB and 
incubated overnight at 37 °C. One millilitre of overnight culture was centrifuged at 9677 g and the supernatant 
removed. Pellets were resuspended in 1 ml of Iscove’s Modified Dulbecco’s Medium (IMDM, Thermofisher) and 
washed once before measuring the  OD600 and adjusted to  OD600 = 0.1 (~ 1 × 107 cfu/ml).
Isolation of human neutrophils. Whole blood from healthy volunteers was isolated using the vacuette 
blood collection system (5–9 ml) on the day of the experiment. Volunteers gave written informed consent. The 
project (Reference 13/WA/0190) was reviewed and the procedures and protocols approved by the local research 
ethics committee, Wales REC 6 (E-mail: Wales.REC6@nhs.uk). Healthy volunteer neutrophils were isolated and 
purified as previously  described67. Freshly drawn blood was collected into citrated (light blue tops) tubes and 
mixed by gentle inversion prior to centrifugation at 350 g for 20 min. The platelet rich plasma was aspirated (for 
serum generation) and the leukocytes remaining in the cellular layer separated from red blood cells through 
dextran (1.25% final concentration) sedimentation. Leukocytes were removed with a Pasteur pipette and washed 
with warm saline, before centrifugation at 350 g for 6 min. The leukocyte cell pellet was resuspended in 3 ml 
of 55% isotonic percoll (GE Healthcare). Then, a tube containing overlaid solutions of percoll was prepared 
comprising 3 ml each of 81%, 70% and the leukocyte suspension in 55% percoll. Then, percoll gradients were 
centrifuged at 720 g for 20 min. Granulocytes were harvested at the 70/81% interface using a Pasteur pipette, 
washed in PBS without calcium and magnesium prior to centrifugation at 230 g for 6 min. Granulocytes were 
resuspended in buffer appropriate for functional assay. Neutrophil were only used at > 95% purity. Neutrophils 
counted by trypan blue staining after treatment with C5a/linezolid alone or in combination had viabilities rang-
ing from 90 to 98%.
Generation of neutrophil dysfunction. Purified neutrophils were resuspended to 1 × 107 viable cells/ml 
in IMDM, then diluted to 1 × 106/ml in IMDM containing 3% autologous serum and recombinant human C5a 
(R and D Systems, Abingdon) at 1–100 ng/ml or untreated  control12. Neutrophils were incubated by rotation 
(10 rpm) at 37 °C for 16 h prior to functional assays. Neutrophil viable counts were re-assessed by trypan blue 
exclusion and adjusted once again to 1 × 106 viable cells/ml.
Linezolid incubation conditions. Linezolid was used at concentrations (0.4–40 mg/ml) consistent with 
tissue and cellular levels of the drug in  humans31–34. Three incubation strategies were used to study the effect of 
linezolid on neutrophils.
1. To study protection against injury: Linezolid (0.4–40 mg/L) was added 1 h prior to C5a injury and washed 
out before addition of C5a;
2. To study inhibition of injury: Linezolid (0.4–40 mg/L) was added in combination with C5a for 16 h;
3. To study restoration of function: Linezolid (0.4–40 mg/L) was added for 1 h following C5a incubation.
After each treatment, neutrophils were centrifuged at 300 g for 5 min, the supernatant removed and cells 
gently re-suspended in appropriate buffer for functional assays. Linezolid was removed prior to all assays involv-
ing MRSA so that it would have no direct antimicrobial effect on the bacteria.
Neutrophil functional assays. 
1. Phagocytosis and killing assays
MRSA  (OD600 = 1) was pre-opsonised with 100% autologous serum for 30 min at 37 °C and then corrected 
to an  OD600 = 0.1 in 3% autologous serum/IMDM. Treated (C5a and linezolid as above) and untreated neutro-
phils at twice normal concentration were exposed for 2 h to pre-opsonised MRSA (multiplicity of infection = 1). 
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Incubation was carried out at constant rotation (10 rpm) at 37 °C. Then 80 μl of MRSA-infected neutrophils 
was used for cytospin preparations (300 rpm for 3 min), air dried and stained with Hemacolor according to the 
manufacturer’s instructions (Millipore Ltd, Watford). For a quantitative measure of phagocytosis, light micros-
copy was used to determine the number of neutrophils containing bacteria within phagosomes with the results 
expressed as a percentage (Supplementary Image 1 and 2). The remaining infected neutrophils were used to assess 
viable counts by gentle lysis in 0.1% Triton X100 for 1 min to release intracellular bacteria. Lysates were diluted, 
plated on TSB agar and incubated overnight at 37 °C prior to determination of viable counts.
2. Superoxide assay
Neutrophil superoxide was assayed by cytochrome c reduction assay as described  previously68. Briefly, treated 
(C5a and linezolid) and untreated neutrophils were re-suspended in 1 ml Hank’s Balanced Salt Solution (HBSS; 
Thermofisher) with calcium at 1 × 107/ml. Then in separate tubes 50 μl of neutrophils (i.e. 500,000 cells), 800 μl 
of cytochrome C (1.25 mg/ml, Sigma Aldrich) and 100 µl of phorbol myristol acetate (PMA, final concentration 
100 nM; Sigma Aldrich) were combined and incubated at 37 °C for 15 min. The reaction was terminated by 
centrifuging at 300×g for 5 min at 4 °C, and the  OD550 of the supernatant determined. The ‘nM of  O2− released 
per million cells’ was calculated from:
3. Transmigration assay
The ability of neutrophils to migrate was assessed by using a Transwell transmigration assay system (pore 
size 3 μm supplied by VWR, Lutterworth, UK), where IL-8 (1–100 ng/ml) was placed in the lower chamber and 
1 × 105 treated (C5a and linezolid as above) or untreated neutrophils added to the top chamber. Following 90 min 
incubation at 37 °C the membrane of the top chamber was wiped very gently with a cotton bud to remove cells 
that had not migrated and fixed for 10 min in 100% methanol. The Transwell filter was then stained with Hema-
color, cut from the Transwell casing and mounted on a microscope slide with a drop of DPX (Sigma Aldrich, 
Gillingham). When dry, transmigration was quantified by counting the number of neutrophils (Supplementary 
Image 3) using a light microscope (100 × oil immersion).
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM) as assessed in Excel. Plots were generated using 
GraphPad Prism software (V5.00 for Windows, GraphPad Software, San Diego California USA). Data were 
subjected to a Shapiro–Wilk normality test and then a one way-analysis of variance (ANOVA) with Tukey’s 
post-hoc test. In Supplementary Fig. 1 a two-way ANOVA and Bonferonni post-hoc test was used. Differences 
between treatment groups were considered statistically significant if p < 0.05.
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